Related references
Note: Only part of the references are listed.The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis
Jasper H. Smalberg et al.
BLOOD (2011)
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
Rakhee Vaidya et al.
BLOOD (2011)
JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation
Fan Liu et al.
CANCER CELL (2011)
MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders
Wanlong Ma et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2011)
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms
Damla Olcaydu et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues
Richard A. Van Etten et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
Sabina I. Swierczek et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
DNMT3A mutations in myeloproliferative neoplasms
F. Stegelmann et al.
LEUKEMIA (2011)
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation
Gabriella Ficz et al.
NATURE (2011)
The Constitutive Activation of Jak2-V617F Is Mediated by a π Stacking Mechanism Involving Phenylalanines 595 and 617
Kavitha Gnanasambandan et al.
BIOCHEMISTRY (2010)
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms
Amy V. Jones et al.
BLOOD (2010)
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
Franz X. Schaub et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms
Fanny Baran-Marszak et al.
BLOOD (2010)
Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
Edwin Chen et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis
Luciana Teofili et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
A. Tefferi et al.
LEUKEMIA (2010)
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis
P. Guglielmelli et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
Charlotte M. Niemeyer et al.
NATURE GENETICS (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability
Nadia Gurvich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Stephen T. Oh et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
Franz X. Schaub et al.
BLOOD (2009)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
Philip A. Beer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
D. Olcaydu et al.
LEUKEMIA (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Sai Li et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
Daniela Capello et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
Nasios Fourouclas et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2
Alexandra Dusa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation
Elisa Rumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Michelle B. Hookham et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
JAK2(V617F): prevalence in a large Chinese hospital population
Xuesong Xu et al.
BLOOD (2007)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor
J Staerk et al.
BLOOD (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
